Home » Stocks » GMAB

Genmab A/S (GMAB)

Stock Price: $44.58 USD 0.56 (1.27%)
Updated Jun 16, 2021 3:47 PM EDT - Market open
Market Cap 28.72B
Revenue (ttm) 1.71B
Net Income (ttm) 886.51M
Shares Out 653.56M
EPS (ttm) 1.34
PE Ratio 33.15
Forward PE 101.01
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $44.58
Previous Close $44.02
Change ($) 0.56
Change (%) 1.27%
Day's Open 43.96
Day's Range 43.96 - 44.92
Day's Volume 694,695
52-Week Range 30.10 - 44.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Company Announcement

2 days ago - GlobeNewsWire

Media Release

Other stocks mentioned: BOLT
2 weeks ago - GlobeNewsWire

Media Release Copenhagen, Denmark, June 1 , 2021 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer , Anthony Pagano and C hief D evelopment O fficer , Judith Klimovsky , wil...

2 weeks ago - GlobeNewsWire

Company Announcement

2 weeks ago - GlobeNewsWire

Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to Genmab A/S (NASDAQ: GMAB) and its partn...

3 weeks ago - Benzinga

COPENHAGEN, Denmark; May 21, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the d...

3 weeks ago - GlobeNewsWire

Company Announcement

1 month ago - GlobeNewsWire

May 5 , 20 21 ; Copenhagen, Denmark ;

1 month ago - GlobeNewsWire

Company Announcement

1 month ago - GlobeNewsWire

Company Announcement

2 months ago - GlobeNewsWire

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...

Other stocks mentioned: SGEN
2 months ago - Business Wire

Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclero...

Other stocks mentioned: NVS
2 months ago - Benzinga

Media Release Copenhagen, Denmark, March 29, 2021

2 months ago - GlobeNewsWire

Company Announcement

3 months ago - GlobeNewsWire

Company Announcement

3 months ago - GlobeNewsWire

Company Announcement

3 months ago - GlobeNewsWire

Introduction

3 months ago - GuruFocus

Company Announcement

3 months ago - GlobeNewsWire

Company Announcement

3 months ago - GlobeNewsWire

Company Announcement

3 months ago - GlobeNewsWire

Company Announcement

3 months ago - GlobeNewsWire

Hijacking the immune system to destroy cancer with bispecific antibodies could be a lucrative business for biotech stocks like Amgen, Genmab and Regeneron Pharmaceuticals. The post The $12 Billion Marke...

Other stocks mentioned: AMGN, REGN
4 months ago - Investors Business Daily

Genmab (NASDAQ: GMAB) and Seagen Inc (NASDAQ: SGEN) have jointly announced the submission of a marketing application with the FDA, seeking accelerated approval for tisotumab vedotin for the treatment of...

4 months ago - Benzinga

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food a...

Other stocks mentioned: SGEN
4 months ago - Business Wire

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...

Other stocks mentioned: ANNX, ASA, BME, BMEZ, BST, BSTZ, GNMSF ...
4 months ago - Seeking Alpha

Company Announcement

4 months ago - GlobeNewsWire

Company Announcement

4 months ago - GlobeNewsWire

Company Announcement

5 months ago - GlobeNewsWire

Media Release Copenhagen, Denmark, January 6, 2021

5 months ago - GlobeNewsWire

Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.

5 months ago - Zacks Investment Research

Media Release COPENHAGEN, Denmark, Jan. 04, 2021

5 months ago - GlobeNewsWire

Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast.

5 months ago - Seeking Alpha

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for tr... [Read more...]

Industry
Biotechnology
Founded
1999
CEO
Jan van de Winkel
Employees
871
Stock Exchange
NASDAQ
Ticker Symbol
GMAB
Full Company Profile

Financial Performance

In 2020, Genmab A/S's revenue was 10.11 billion, an increase of 88.43% compared to the previous year's 5.37 billion. Earnings were 4.76 billion, an increase of 119.67%.

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Genmab A/S stock is "Buy." The 12-month stock price forecast is 42.21, which is a decrease of -5.32% from the latest price.

Price Target
$42.21
(-5.32% downside)
Analyst Consensus: Buy